11 results on '"Gao WY"'
Search Results
2. Distribution of fibroblast growth factors and their roles in skin fibroblast cell migration.
- Author
-
Song YH, Zhu YT, Ding J, Zhou FY, Xue JX, Jung JH, Li ZJ, and Gao WY
- Subjects
- Animals, Fibroblast Growth Factors analysis, Fibroblast Growth Factors genetics, Fibroblasts metabolism, Gene Expression, Male, Mice, Mice, Inbred C57BL, NIH 3T3 Cells, Phylogeny, Skin metabolism, Wound Healing, Cell Movement, Fibroblast Growth Factors metabolism, Fibroblasts cytology, Skin cytology
- Abstract
Fibroblast growth factor (FGF)2/basic FGF is a member of the fibroblast growth factor family. Its function in skin wound healing has been well-characterized. However, the function of other FGFs in skin tissues remains to be elucidated. In the present study, FGF expression patterns in heart, liver, skin and kidney tissues were analyzed. Notably, in contrast to other tissues, only four FGFs, FGF2, 7, 10 and 21, were dominant in the skin. To examine FGF function in the wound healing process, mouse NIH3T3 fibroblast cells were treated with FGF2, FGF10 and FGF21, and cell migration was monitored. The results revealed that FGF treatment promoted cell migration, which is an important step in wound healing. In addition, FGF treatment enhanced the activity of c-Jun N-terminal kinase (JNK), a key regulator of fibroblast cell migration. To analyze its role in cell migration, FGF7 was overexpressed in fibroblast cells via a lentivirus system; however, this did not change cell migration speed. FGF2, 7, 10 and 21 were highly expressed in skin tissue, and all except FGF7 regulated fibroblast cell migration and activated JNK. The results of the present study increase our understanding of the role of FGFs in skin wound healing.
- Published
- 2016
- Full Text
- View/download PDF
3. NADPH oxidase-2 is a key regulator of human dermal fibroblasts: a potential therapeutic strategy for the treatment of skin fibrosis.
- Author
-
Zhang GY, Wu LC, Dai T, Chen SY, Wang AY, Lin K, Lin DM, Yang JQ, Cheng B, Zhang L, Gao WY, and Li ZJ
- Subjects
- Cells, Cultured, Collagen biosynthesis, Collagen genetics, Enzyme Inhibitors pharmacology, Fibrosis, Gene Knockdown Techniques, Humans, Keloid enzymology, Keloid genetics, Keloid therapy, MAP Kinase Signaling System, Membrane Glycoproteins antagonists & inhibitors, Membrane Glycoproteins genetics, NADPH Oxidase 2, NADPH Oxidases antagonists & inhibitors, NADPH Oxidases genetics, Onium Compounds pharmacology, RNA, Messenger genetics, RNA, Messenger metabolism, RNA, Small Interfering genetics, Reactive Oxygen Species metabolism, Smad Proteins metabolism, Transcription Factor AP-1 metabolism, Transforming Growth Factor beta1 metabolism, Fibroblasts enzymology, Membrane Glycoproteins metabolism, NADPH Oxidases metabolism, Skin enzymology
- Abstract
The proliferation of human skin dermal fibroblasts (HDFs) is a critical step in skin fibrosis, and transforming growth factor-beta1 (TGF-β1) exerts pro-oxidant and fibrogenic effects on HDFs. In addition, the oxidative stress system has been implicated in the pathogenesis of skin disease. However, the role of NADPH oxidase as a mediator of TGF-β1-induced effects in HDFs remains unknown. Thus, our aim was to investigate the role of NADPH in human skin dermal fibroblasts. Primary fibroblasts were cultured and pretreated with various stimulants. Real-time Q-PCR and Western blotting analyses were used for mRNA and protein detection. In addition, siRNA technology was applied for gene knock-down analysis. Hydrogen peroxide production and 2',7'-dichlorofluorescein diacetate (DCFDA) measurement assay were performed. Here, our findings demonstrated that HDFs express key components of non-phagocytic NADPH oxidase mRNA. TGF-β1 induced NOX2 and reactive oxygen species formation via NADPH oxidase activity. In contrast, NOX3 was barely detectable, and other NOXs did not display significant changes. In addition, TGF-β1 phosphorylated MAPKs and increased activator protein-1 (AP-1) in a redox-sensitive manner, and NOX2 suppression inhibited baseline and TGF-β1-mediated stimulation of Smad2 phosphorylation. Moreover, TGF-β1 stimulated cell proliferation, migration, collagen I and fibronectin expression, and bFGF and PAI-1 secretion: these effects were attenuated by diphenylene iodonium (DPI), an NADPH oxidase inhibitor, and NOX2 siRNA. Importantly, NOX2 siRNA suppresses collagen production in primary keloid dermal fibroblasts. These findings provide the proof of concept for NADPH oxidase as a potential target for the treatment of skin fibrosis., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
4. [Effects of agonists of PPAR-gamma on angiotensin II-induced proliferation and extracellular matrix synthesis in hypertrophic scar fibroblasts].
- Author
-
Lin K, Lü L, Gao WY, He ZL, and Zhang GY
- Subjects
- Cell Proliferation drug effects, Cells, Cultured, Collagen Type I biosynthesis, Fibroblasts metabolism, Fibroblasts pathology, Fibronectins biosynthesis, Humans, Angiotensin II pharmacology, Cicatrix, Hypertrophic metabolism, Extracellular Matrix drug effects, Fibroblasts drug effects, PPAR gamma agonists
- Abstract
Objective: To study the effects of peroxisome proliferator-activated receptor gamma agonists on angiotensin II-induced cellular response in cultured fibroblasts derived from patients with hypertrophic scars, so as to investigate its effects on preventing the formation of hypertrophic scars., Methods: Fibroblasts were freshly isolated from hypertrophic scars and cultured with angiotensin II, rosiglitazone and GW9662 at a certain concentration. Fibroblasts proliferation were assessed via Cell Counting Kit-8; the mRNA and protein expressions of Collagen I and Fibronectin (FN) were determined by quantitative real-time RT-PCR and Western blotting., Results: The absorbance of CCK-8 and relative expression of Collagen I, FN mRNA and protein were 1.082 5 +/- 0.007, 6.45 +/- 0.97, 4.92 +/- 0.86, 2.92 +/- 0.41, 2.78 +/- 1.04 in Ang II group; 0.722 4 +/- 0.012, 1.82 +/- 0.34, 1.78 +/- 0.27, 1.57 +/- 0.46, 1.68 +/- 0.39 in Ros + Ang II group; 0.554 7 +/- 0.012, 0.97 +/- 0.12, 1.07 +/- 1.08, 1.05 +/- 0.43, 1.14 +/- 0.36 in Ros group; 1.056 0 +/- 0.005, 5.83 +/- 0.24, 4.47 +/- 0.32, 2.69 +/- 0.35, 2.62 +/- 0.27 in GW9662 + ros + Ang II group. The results showed a significant difference between the Ang II group and the control group (P < 0.05). The effect of Ang II could be markedly inhibited by Ros (P < 0.05). In addition, Ros did not influence cell proliferation and production of extracellular matrix (P > 0.05). There was a significant difference between the GW9662 + Ros + Ang II group and the Ros + Ang II (P < 0.05)., Conclusions: PPAR-gamma agonists inhibit Ang II-induced proliferation and extracellular matrix synthesis effectively in the hypertrophic scar fibroblasts. Thus PPAR-gamma agonists may have potential therapeutic effect for hypertrophic scar.
- Published
- 2013
5. Caveolin 1 inhibits transforming growth factor-β1 activity via inhibition of Smad signaling by hypertrophic scar derived fibroblasts in vitro.
- Author
-
Zhang GY, He B, Liao T, Luan Q, Tao C, Nie CL, Albers AE, Zheng X, Xie XG, and Gao WY
- Subjects
- Adolescent, Adult, Culture Media, Serum-Free pharmacology, DNA Primers genetics, Female, Humans, Male, Peptides chemistry, Phosphorylation, Signal Transduction, Transfection, Caveolin 1 physiology, Cicatrix, Hypertrophic metabolism, Fibroblasts metabolism, Smad Proteins metabolism, Transforming Growth Factor beta1 antagonists & inhibitors
- Published
- 2011
- Full Text
- View/download PDF
6. Vitamin D: a novel therapeutic approach for keloid, an in vitro analysis.
- Author
-
Zhang GY, Cheng T, Luan Q, Liao T, Nie CL, Zheng X, Xie XG, and Gao WY
- Subjects
- Adolescent, Adult, Blotting, Western, Cell Proliferation drug effects, Cell Survival drug effects, Cells, Cultured drug effects, Collagen metabolism, Female, Fibroblasts cytology, Fibroblasts metabolism, Hepatocyte Growth Factor metabolism, Humans, Immunosorbent Techniques, Keloid metabolism, Keloid pathology, Male, Phenotype, Receptors, Calcitriol metabolism, Reverse Transcriptase Polymerase Chain Reaction, Transforming Growth Factor beta1 pharmacology, Young Adult, Dihydroxycholecalciferols pharmacology, Fibroblasts drug effects, Keloid drug therapy, Vitamins pharmacology
- Abstract
Background: Vitamin D and its metabolites play an important role in calcium homeostasis, bone remodelling, hormone secretion, cell proliferation and differentiation. Recent studies also suggest a beneficial role of vitamin D in slowing the progression of tissue fibrosis. However, their effects on dermal fibrosis and keloids are unknown. Objectives To investigate the effect of 1,25-dihydroxyvitamin D3 (1,25D) in the pathogenesis of tissue fibrosis by keloid fibroblasts (KFs)., Methods: KFs were cultured and exposed to different concentrations of 1,25D in the presence or absence of transforming growth factor (TGF)-β1. KF phenotypes and protein production were analysed by real-time reverse transcriptase-polymerase chain reaction, Western blot, immunofluorescence and multiplex enzyme-linked immunosorbent assay techniques. Collagen synthesis was evaluated by measuring (3) H-proline incorporation. The effect of 1,25D on cell proliferation and viability was evaluated by Formazan assay, proliferating cell nuclear antigen expression and the colorimetric conversion of 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide., Results: We confirmed the presence of vitamin D receptors (VDRs) in cultured keloid fibroblasts. Fibroblasts transfected with a vitamin D response element reporter construct and exposed to the active vitamin D metabolite 1,25D showed increased promoter activity indicating VDR functionality in these cells. Incubation of KFs with 1,25D suppressed TGF-β1-induced collagen type I, fibronectin and α-smooth muscle actin expression. 1,25D also modulated plasminogen activator inhibitor-1 and matrix metalloproteinase-9 expression induced by TGF-β1. Interestingly, 1,25D induced hepatocyte growth factor mRNA expression and protein secretion in keloid fibroblasts., Conclusions: This study highlights key mechanistic pathways through which vitamin D decreases fibrosis, and provides a rationale for studies to test vitamin D supplementation as a preventive and/or early treatment strategy for keloid and related fibrotic disorders., (© 2011 The Authors. BJD © 2011 British Association of Dermatologists.)
- Published
- 2011
- Full Text
- View/download PDF
7. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts.
- Author
-
Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, Chen XL, Yu Q, Jiang LF, Zhou FY, Li XY, Yang JQ, Chu TG, and Gao WY
- Subjects
- Cell Proliferation drug effects, Cell Survival drug effects, Cells, Cultured, Collagen Type I metabolism, Dose-Response Relationship, Drug, Fibronectins metabolism, Humans, L-Lactate Dehydrogenase metabolism, PPAR gamma genetics, PPAR gamma metabolism, RNA, Messenger metabolism, Reverse Transcriptase Polymerase Chain Reaction, Troglitazone, Chromans pharmacology, Extracellular Matrix metabolism, Fibroblasts metabolism, Hypoglycemic Agents pharmacology, PPAR gamma agonists, Skin cytology, Thiazolidinediones pharmacology, Transforming Growth Factor beta1 metabolism
- Abstract
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists are increasingly used in patients with diabetes, and some studies have suggested a beneficial effect on organ fibrosis, but their effects on dermal cell growth and extracellular matrix (ECM) turnover are unknown. To investigate the effect of the PPAR-gamma agonist troglitazone on cell growth and matrix production in human dermal fibroblasts (HDF), HDF were cultured and grown in a different concentration of troglitazone. PPAR-gamma expression and matrix production were measured in HDF in the presence of troglitazone. The mRNA expressions of TGF-beta1, collagen I (Col I) and fibronectin (FN) were determined by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR). The protein of transforming growth factor-beta1 (TGF-beta1) was determined by enzyme-linked immunosorbent assay (ELISA) and proteins of Col I and FN were determined by Western blotting. The mRNA expression of TGF-beta1, Col I and FN were significantly decreased in HDF in 15-30 micromol l(-1) troglitazone compared to the control group with Dulbecco's modified Eagle's medium (P<0.01). An obvious decrease of TGF-beta1 protein was found in troglitazone-treated groups as compared to the control group (P<0.05). Exposure of HDF to troglitazone reduced col I secretion (P<0.05), and fibronectin secretion (P<0.05). This study suggests that PPAR-gamma agonist will provide a novel approach with therapeutic potential in dermal fibrosis, such as hypertrophic scar, keloid and so on., (Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
8. Angiotensin II activates connective tissue growth factor and induces extracellular matrix changes involving Smad/activation and p38 mitogen-activated protein kinase signalling pathways in human dermal fibroblasts.
- Author
-
Zhang GY, Li X, Yi CG, Pan H, He GD, Yu Q, Jiang LF, Xu WH, Li ZJ, Ding J, Lin DS, and Gao WY
- Subjects
- Enzyme Inhibitors pharmacology, Fibronectins metabolism, Fibrosis, Humans, Signal Transduction, Skin pathology, Smad7 Protein metabolism, Angiotensin II metabolism, Connective Tissue Growth Factor metabolism, Extracellular Matrix metabolism, Fibroblasts metabolism, Receptor, Angiotensin, Type 1 metabolism, Receptor, Angiotensin, Type 2 metabolism, Skin metabolism, Smad Proteins metabolism, p38 Mitogen-Activated Protein Kinases metabolism
- Abstract
Angiotensin II (Ang II) stimulation has been shown to regulate proliferation of skin fibroblasts and the production of extracellular matrix, which are very important processes in skin wound healing and fibrosis; however, there is little knowledge about the mechanisms involved in this process. We investigated the molecular aspects of this system with regards to Ang II in human dermal fibroblasts (HDF) and its potential role in fibrosis. Fibroblasts derived from human skin were subjected to examine differential relative gene and protein expression after transfection with specific reporter expression vectors and Ang II in vitro. In growth-arrested HDFs, Ang II treatment for 20 min caused acute activation of Smad2 phosphorylation, Smad overexpression and Smad-dependent gene transcription. The angiotensin type 1 (AT1) antagonist losartan diminished Ang II-induced Smad activation. The blockade of endogenous transforming growth factor-beta1 did modify the activation of Smad caused by Ang II. The p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 diminished Ang II-induced Smad2 phosphorylation. Transient transfection with Smad7, which interferes with receptor-mediated activation of Smad2, diminished Ang II-induced connective tissue growth factor promoter activation, gene and protein expression and fibronectin, type I procollagen and type III procollagen overexpression, showing that Smad activation is involved in Ang II-induced dermal fibrosis. Our results show that Ang II activation of Smad2 occurs via the AT1 receptor, but not the AT2 receptor. Activation of Smad2 required p38 MAPK but not p42/p44 MAPK or the epidermal growth factor receptor.
- Published
- 2009
- Full Text
- View/download PDF
9. Activation of peroxisome proliferator-activated receptor-gamma inhibits transforming growth factor-beta1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro.
- Author
-
Zhang GY, Cheng T, Zheng MH, Yi CG, Pan H, Li ZJ, Chen XL, Yu Q, Jiang LF, Zhou FY, Li XY, Yang JQ, Chu TG, and Gao WY
- Subjects
- Cell Growth Processes drug effects, Cells, Cultured, Cicatrix, Hypertrophic genetics, Cicatrix, Hypertrophic immunology, Cicatrix, Hypertrophic pathology, Connective Tissue pathology, Connective Tissue Growth Factor genetics, Connective Tissue Growth Factor immunology, Dose-Response Relationship, Immunologic, Extracellular Matrix, Fibroblasts immunology, Fibroblasts pathology, Humans, Oxazoles pharmacology, PPAR gamma genetics, PPAR gamma immunology, Prostaglandin D2 analogs & derivatives, Prostaglandin D2 pharmacology, Transcriptional Activation drug effects, Transcriptional Activation immunology, Transforming Growth Factor beta genetics, Transforming Growth Factor beta immunology, Tyrosine analogs & derivatives, Tyrosine pharmacology, Cicatrix, Hypertrophic metabolism, Connective Tissue Growth Factor metabolism, Fibroblasts metabolism, PPAR gamma metabolism, Transforming Growth Factor beta metabolism
- Abstract
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands have been recently reported to have beneficial effects on organ fibrosis. However, their effects on extracellular matrix (ECM) turnover in hypertrophic scar fibroblasts (HSFs), and the related molecular mechanisms are unknown. HSFs were cultured and exposed to different concentration PPAR-gamma ligands in the presence of transforming growth factor-beta1 (TGF-beta1). In growth-arrested HSFs, a PPAR-gamma natural ligand (15-deoxy-D12,14-prostaglandin J2, 15d-PGJ2) and a synthetic ligand (GW7845) dose-dependently attenuated TGFbeta1-induced expression of Connective tissue growth factor (CTGF), collagens and fibronectin. Furthermore, the suppression of CTGF mRNA and protein expression are relieved by pretreatment with an antagonist of PPAR-gamma (GW9662). Moreover, GW7845 and 15d-PGJ2 partially inhibited the expression and phosphorylation of the TGF-beta1/Smad pathway. These results suggest that in TGFbeta1-stimulated HSFs, PPAR-gamma ligands caused an antiproliferative effect and reduced ECM production through mechanisms that included reducing CTGF expression, and a crosstalk between PPAR-gamma and Smad may be involved in the inhibitory effects of PPAR-gamma ligands.
- Published
- 2009
- Full Text
- View/download PDF
10. Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid.
- Author
-
Zhang GY, Gao WY, Li X, Yi CG, Zheng Y, Li Y, Xiao B, Ma XJ, Yan L, Lu KH, Han Y, and Guo SZ
- Subjects
- Adolescent, Adult, Blotting, Western, DNA Topoisomerases, Type I genetics, Dose-Response Relationship, Drug, Female, Humans, Keloid genetics, Keloid pathology, Male, Reverse Transcriptase Polymerase Chain Reaction, Skin pathology, Wound Healing drug effects, Young Adult, Camptothecin pharmacology, Camptothecin therapeutic use, Collagen biosynthesis, Collagen drug effects, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Fibroblasts drug effects, Fibroblasts metabolism, Keloid drug therapy
- Abstract
Keloids are distinguished by substantial deposition of collagen in the dermis, resulting in an imbalanced production and aggregation of extra cellular matrix. This study was undertaken to evaluate the effects of the topoisomerase I inhibitor camptothecin (CPT) on collagen synthesis in the activated dermal fibroblasts from healthy donors and patients with keloid. The fibroblasts were cultured in the presence or absence of CPT. Cellular toxicity assay was determined by MTT analysis. The expression of type I collagen and type III collagen was studied both at the transcriptional and post-transcriptional levels, using conventional quantitative real-time reverse transcription PCR and Western blotting. Results showed that there was predominantly a clear and dose-dependent decrease in the synthesis of collagen 1, not collagen 3, in keloid fibroblasts without significantly cellular toxicity. The CPT had an activity on the regulation of the ratio of type I/III collagen in the metabolism of keloid fibroblasts by inhibiting the secretion of type I collagen. The data suggest that the inhibitory effect of CPT, a topoisomerase I inhibitor, on collagen synthesis may be an effective treatment for limiting fibrosis in keloid patients.
- Published
- 2009
- Full Text
- View/download PDF
11. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
- Author
-
Zhang GY, Yi CG, Li X, Ma B, Li ZJ, Chen XL, Guo SZ, and Gao WY
- Subjects
- Adolescent, Adult, Blotting, Western, Female, Fibroblasts drug effects, Fibrosis metabolism, Humans, Male, PPAR gamma agonists, PPAR gamma metabolism, Smad Proteins metabolism, Troglitazone, Young Adult, Chromans therapeutic use, Collagen Type I metabolism, Fibroblasts metabolism, Hypoglycemic Agents therapeutic use, Keloid metabolism, Thiazolidinediones therapeutic use, Transforming Growth Factor beta1 metabolism
- Abstract
Background: Peroxisome proliferator-activated receptor (PPAR)-gamma agonists are increasingly used in patients with diabetes and some studies have suggested a beneficial effect on organ fibrosis. However their effects on dermal fibrosis in keloids are unknown., Objective: To investigate the effect of the PPAR-gamma agonist troglitazone on transforming growth factor (TGF)-beta1-induced collagen type I expression in keloid fibroblasts., Methods: Keloid fibroblasts were cultured and exposed to different concentrations of troglitazone in the presence of TGF-beta1. The mRNA expression of PPAR-gamma was determined by semiquantitative reverse transcriptase-polymerase chain reaction. The protein of PPAR-gamma, Smad2, Smad3, phoshpo-Smad2/3 and collagen type I was determined by Western blotting and collagen synthesis was evaluated by measuring (3)H-proline incorporation. The effect of troglitazone on cell viability was evaluated by the colorimetric conversion of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide., Results: PPAR-gamma was expressed at a moderate level in keloid fibroblasts. Troglitazone depressed TGF-beta1-stimulated collagen type I expression and collagen synthesis in keloid fibroblasts in a concentration-dependent manner. Moreover, troglitazone inhibited expression and phosphorylation of TGF-beta1-induced Smad2/3. Cell viability was unaffected. These inhibitory effects of troglitazone were reversed by the PPAR-gamma-specific antagonist GW9662., Conclusions: Our data suggest that PPAR-gamma is present in keloid fibroblasts and PPAR-gamma activation inhibits TGF-beta1-induced collagen type I expression at least in part by decreasing collagen synthesis. PPAR-gamma may be a promising therapeutic target for keloids.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.